Neurocognitive dysfunction in subjects at clinical high risk for psychosis: A meta-analysis

被引:37
|
作者
Zheng, Wei [1 ]
Zhang, Qing-E. [2 ,3 ,4 ]
Cai, Dong-Bin [5 ]
Ng, Chee H. [6 ]
Ungvari, Gabor S. [7 ]
Ning, Yu-Ping [1 ]
Xiang, Yu-Tao [8 ]
机构
[1] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Guangdong, Peoples R China
[2] Natl Clin Res Ctr Mental Disorders, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Anding Hosp, Beijing Inst Brain Disorders, Ctr Depress, Beijing, Peoples R China
[4] Beijing Anding Hosp, Capital Med Univ, Mood Disorders Ctr, Beijing, Peoples R China
[5] Guangzhou Univ Chinese Med, Clin Med Coll 1, Clin Chinese Med, Guangzhou, Guangdong, Peoples R China
[6] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia
[7] Univ Notre Dame Australia, Graylands Hosp, Perth, WA, Australia
[8] Univ Macau, Fac Hlth Sci, Unit Psychiat, Taipa, Macao, Peoples R China
关键词
Schizophrenia; Psychosis; Clinical high risk for psychosis; Neurocognitive function; MCCB; Meta-analysis; ULTRA-HIGH-RISK; CONSENSUS COGNITIVE BATTERY; SOCIAL COGNITION; YOUNG-ADULTS; SCHIZOPHRENIA; DEFICITS; INDIVIDUALS; STATE; 1ST-EPISODE; HETEROGENEITY;
D O I
10.1016/j.jpsychires.2018.05.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Findings of neurocognitive dysfunction in subjects at Clinical High Risk for Psychosis (CHR-P) have been controversial. This meta-analysis systematically examined studies of neurocognitive functions using the MATRICS Consensus Cognitive Battery (MCCB) in CHR-P. An independent literature search of both English and Chinese databases was conducted by two reviewers. Standardized mean difference (SMD) was calculated using a random effects model to evaluate the effect size of the meta-analytic results. Six case-control studies (n = 396) comparing neurocognitive functions between CHR-P subjects (n = 197) and healthy controls (n = 199) using the MCCB were identified; 4 (66.7%) studies were rated as "high quality". Compared to healthy controls, CHR-P subjects showed impairment with large effect size in overall cognition (n = 128, SMD = 1.00, 95%CI: 1.38, 0.63, P < 0.00001; 12 = 2%), processing speed (SMD = 1.21) and attention/vigilance (SMD = 0.83), and with medium effect size in working memory (SMD = 0.76), reasoning and problem solving (SMD = 0.71), visual (SMD = 0.68) and verbal learning (SMD = 0.67). No significant difference between CHR-P subjects and controls was found regarding social cognition (SMD = 0.33, 95%CI: 0.76, 0.10, P = 0.14; 12 = 70%) with small effect size. Apart from social cognition, CHR-P subjects performed worse than healthy control in all MCCB cognitive domains, particularly in processing speed, attention/vigilance and working memory.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 50 条
  • [31] TREATMENT AND GLOBAL FUNCTIONING IN YOUTH AT CLINICAL HIGH RISK FOR PSYCHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Devoe, Dan
    Addington, Jean
    SCHIZOPHRENIA BULLETIN, 2019, 45 : S214 - S214
  • [32] Neurocognitive predictors of metacognition in individuals at clinical high risk for psychosis
    Shakeel, M. K.
    Lu, L.
    Woods, S. W.
    Perkins, D. O.
    Addington, J.
    BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY, 2020, 48 (02) : 248 - 252
  • [33] Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis
    de Pablo, Gonzalo Salazar
    Davies, Cathy
    de Diego, Hector
    Solmi, Marco
    Shin, Jae Il
    Carvalho, Andre F.
    Radua, Joaquim
    Fusar-Poli, Paolo
    EUROPEAN PSYCHIATRY, 2021, 64 (01)
  • [34] META-ANALYSIS OF COGNITIVE DEFICITS IN ULTRA-HIGH RISK TO PSYCHOSIS
    Bora, Emre
    Pantelis, Christos
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S141 - S142
  • [35] Neurocognitive Functioning of Adolescents with Clinical High Risk for Psychosis, other Psychiatric Symptoms, and Psychosis
    Orlandi, M.
    Iorio, M.
    Rogantini, C.
    Vecchio, A.
    Coci, C.
    Casini, E.
    Borgattii, R.
    Mensi, M.
    EUROPEAN PSYCHIATRY, 2022, 65 : S322 - S322
  • [36] Clinical and neurocognitive profiles of a combined clinical high risk for psychosis and clinical control sample: latent class analysis
    Stuble, Miriam
    Schultze-Lutter, Frauke
    Kaess, Michael
    Franscini, Maurizia
    Traber-Walker, Nina
    Walger, Petra
    Schimmelmann, Benno G.
    Vogeley, Kai
    Kambeitz, Joseph
    Kindler, Jochen
    Michel, Chantal
    BJPSYCH OPEN, 2024, 10 (06):
  • [37] Various neurocognitive deficits and conversion risk in individuals at clinical high risk for psychosis
    Mourik, Kees
    Decrescenzo, Paula
    Brucato, Gary
    Gill, Kelly E.
    Arndt, Leigh
    Kimhy, David
    Keilp, John G.
    Girgis, Ragy R.
    EARLY INTERVENTION IN PSYCHIATRY, 2017, 11 (03) : 250 - 254
  • [38] Social cognition in people at clinical high risk for psychosis: meta-analysis, neural basis and predictive relevance
    Aleman, Andre
    EARLY INTERVENTION IN PSYCHIATRY, 2014, 8 : 8 - 8
  • [39] Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis
    Radua, Joaquim
    Davies, Cathy
    Fusar-Poli, Paolo
    SCHIZOPHRENIA RESEARCH, 2021, 227 : 20 - 27
  • [40] Prevalence of tobacco smoking in people at clinical high-risk for psychosis: Systematic review and meta-analysis
    De Micheli, Andrea
    Provenzani, Umberto
    Solmi, Marco
    Van Pabst, Albertine Van Lawick
    Youssef, Enas
    McGuire, Philip
    Fusar-Poli, Paolo
    SCHIZOPHRENIA RESEARCH, 2023, 254 : 109 - 115